Prolonged attenuation of the reinforcing strength of cocaine by chronic d-amphetamine in rhesus monkeys

Neuropsychopharmacology

Volumn 36, Issue 2, 2011, Pages 539-547

  Czoty, Paul W ^a   Gould, Robert W ^a   Martelle, Jennifer L ^a   Nader, Michael A ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

animal model; cocaine; d amphetamine; drug abuse; medication development; rhesus monkey

Indexed keywords

COCAINE; DEXAMPHETAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; COCAINE DEPENDENCE; DOSE RESPONSE; DRUG SELF ADMINISTRATION; DRUG SENSITIVITY; LONG TERM CARE; MALE; NONHUMAN; PERFORMANCE; PRIORITY JOURNAL; REINFORCEMENT; RHESUS MONKEY; TREATMENT WITHDRAWAL;

ANIMALS; COCAINE; COCAINE-RELATED DISORDERS; DEXTROAMPHETAMINE; DISEASE MODELS, ANIMAL; DOPAMINE UPTAKE INHIBITORS; DRUG ADMINISTRATION SCHEDULE; MACACA MULATTA; MALE; REINFORCEMENT (PSYCHOLOGY); REWARD; SELF ADMINISTRATION; TIME FACTORS;

EID: 78650178776     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2010.185     Document Type: Article

References (40)

1. Ator NA, Griffiths RR (2003). Principles of drug abuse liability assessment in laboratory animals. Drug Alcohol Depend 5: S55-S72.
2. Barrett AC, Miller JR, Dohrmann JM, Caine SB (2004). Effects of dopamine indirect agonists and selective D1-like and D2-like agonists and antagonists on cocaine self-administration and food maintained responding in rats. Neuropsychopharmacology 47(Suppl 1): 256-273.
3. Beckett AH, Rowland M (1965). Urinary excretion kinetics of amphetamine in man. J Pharm Pharmacology 17: 628-639.
4. Bergman J (2008). Medications for stimulant abuse: agonist-based strategies and preclinical evaluation of the mixed-action D2 partial agonist aripiprazole (Abilify). Exp Clin Psychopharmacol 16: 475-483.
5. Carroll FI, Howell LL, Kuhar MJ (1999). Pharmacotherapies for treatment of cocaine abuse: preclinical aspects. J Med Chem 42: 2721-2736.
6. Chiodo KA, Lack CM, Roberts DC (2008). Cocaine self-administration reinforced on a progressive ratio schedule decreases with continuous D-amphetamine treatment in rats. Psychopharmacology 200: 465-473.
7. Chiodo KA, Roberts DC (2009). Decreased reinforcing effects of cocaine following 2 weeks of continuous d-amphetamine treatment in rats. Psychopharmacology 206: 447-456.
8. Czoty PW, Martelle JL, Nader MA (2006). Influence of abstinence and conditions of cocaine access on the reinforcing strength of cocaine in nonhuman primates. Drug Alcohol Depend 85: 213-220.
9. Czoty PW, Martelle JL, Nader MA (2010). Effects of chronic d-amphetamine on the reinforcing strength of cocaine in rhesus monkeys. Psychopharmacology 209: 375-382.
10. de Wit H, Stewart J (1983). Drug reinstatement of heroin-reinforced responding in the rat. Psychopharmacology 79: 29-31.
11. Fleming PM, Roberts D (1994). Is the prescription of amphetamine justified as a harm reduction measure? J R Soc Health 114: 127-131.
12. Foltin RW, Evans SM (1999). The effects of d-amphetamine on intake of food and a sweet fluid containing cocaine. Pharmacol Biochem Behav 62: 457-464.
13. Gerber GJ, Stretch R (1975). Drug-induced reinstatement of extinguished self-administration behavior in monkeys. Pharmacol Biochem Behav 3: 1055-1061.
14. Grabowski J, Rhoades H, Schmitz J, Stotts A, Daruzska LA, Creson D et al. (2001). Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. J Clin Psychopharmacology 21: 522-526.
15. Grabowski J, Shearer J, Merrill J, Negus SS (2004a). Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addict Behav 29: 1439-1464.
16. Grabowski J, Rhoades H, Stotts A, Cowan K, Kopecky C, Dougherty A et al. (2004b). Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials. Neuropsychopharmacology 29: 969-981.
17. Griffiths RR, Bigelow GE, Henningfield JE (1980). Similarities in animal and human drug-taking behavior. In Mello, NK (ed.). Advances in Substance Abuse, vol 1. JAI Press: Greenwich, CT, pp 1-90.
18. Haddad P (1998). The SSRI discontinuation syndrome. J Psychopharmacol 12: 305-313.
19. Haney M, Spealman R (2008). Controversies in translational research: drug self-administration. Psychopharmacology 199: 403-419.
20. Haney M, Ward AS, Foltin RW, Fishman MW (2001). Effects of ecopipam, a selective dopamine D1 antagonist on smoked cocaine self-administration by humans. Psychopharmacology 155: 330-337.
21. Herin DV, Rush CR, Grabowski J (2010). Agonist-like pharmacotherapy for stimulant dependence: preclinical, human laboratory, and clinical studies. Ann NY Acad Sci 1187: 76-100.
22. Lile JA, Nader MA (2003). The abuse liability and therapeutic potential of drugs evaluated for cocaine addiction as predicted by animal models. Curr Neuropharmacol 1: 21-46.
23. Lile JA, Wang Z, Woolverton WL, France JE, Gregg TC, Davies HM et al. (2003). The reinforcing efficacy of psychostimulants in rhesus monkeys: the role of pharmacokinetics and pharmaco-dynamics. J Pharmacol Exp Ther 307: 356-366.
24. Mansbach RS, Balster RL (1993). Effects of mazindol on behavior maintained or occasioned by cocaine. Drug Alcohol Depend 31: 183-191.
25. Martelle JL, Czoty PW, Nader MA (2008). Effects of time-out duration on the reinforcing strength of cocaine assessed under a progressive-ratio schedule in rhesus monkeys. Behavioural Pharmacology 19: 743-746.
26. Mello NK, Negus SS (1996). Preclinical evaluation of pharmacotherapies for treatment of cocaine and opioid abuse using drug self-administration procedures. Neuropsychopharmacology 14: 375-424.
27. Negus SS (2003). Rapid assessment of choice between cocaine and food in rhesus monkeys: effects of environmental manipulations and treatment with d-amphetamine and flupenthixol. Neuropsychopharmacology 28: 909-931.
28. 00 medications for cocaine dependence: studies in assays of cocaine discrimination and cocaine self-administration in rhesus monkeys. J Pharmacol Exp Ther 320: 627-636.
29. Negus SS, Mello NK (2003a). Effects of chronic d-amphetamine treatment on cocaine- and food-maintained responding under a progressive-ratio schedule in rhesus monkeys. Psychopharmacology 167: 324-332.
30. Negus SS, Mello NK (2003b). Effects of chronic d-amphetamine treatment on cocaine- and food-maintained responding under a second-order schedule in rhesus monkeys. Drug Alcohol Depend 70: 39-52.
31. Platt DM, Rowlett JK, Spealman RD (2002). Behavioral effects of cocaine and dopaminergic strategies for preclinical medication development. Psychopharmacology 163: 265-282.
32. Richardson NR, Roberts DCS (1996). Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy. J Neurosci Methods 66: 1-11.
33. Romach MK, Glue P, Kampman K, Kaplan HL, Somer GR, Poole S et al (1999). Attenuation of the euphoric effects of cocaine by the dopamine D1/D5 antagonist ecopipam (SCH 39166). Arch Gen Psychiatry 56: 1101-1106.
34. Rothman RB, Blough BE, Woolverton WL, Anderson KG, Negus SS, Mello NK et al. (2005). Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration. J Pharmacol Exp Ther 313: 1361-1369.
35. Rothman RB, Glowa JR (1995). A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development. Focus on GBR 12909. Mol Neurobiol 11: 1-19.
36. Shearer J, Wodak A, van Beek I, Mattick RP, Lewis J (2003). Pilot randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence. Addiction 98: 1137-1141.
37. Sorensen G, Sager TN, Petersen JH, Brennum LT, Thogersen P, Hee Bengsten C et al. (2008). Aripiprazole blocks acute self-administration of cocaine and is not self-administered in mice. Psychopharmacology 199: 37-46.
38. Thomsen M, Fink-Jensen A, Woldbye DP, Wortwein DP, Sagen TN, Holm R et al. (2008). Effects of acute and chronic aripiprazole treatment on choice between cocaine self-administration and food under a concurrent schedule of reinforcement in rats. Psychopharmacology 201: 43-53.
39. Vocci F, Ling W (2005). Medications development: successes and challenges. Pharmacol Ther 108: 94-108.
40. White R (2000). Dexamphetamine substitution in the treatment of amphetamine abuse: an initial investigation. Addiction 95: 229-238.